WS Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

WS Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15,885	Closed	-$760K	–	69
2023 Q4	$760K	Hold	15,885	–	–	0.05%	64
2023 Q3	$566K	Hold	15,885	–	–	0.05%	65
2023 Q2	$733K	Hold	15,885	–	–	0.06%	59
2023 Q1	$637K	Hold	15,885	–	–	0.07%	56
2022 Q4	$736K	Hold	15,885	–	–	0.06%	61
2022 Q3	$658K	Hold	15,885	–	–	0.06%	64
2022 Q2	$948K	Hold	15,885	–	–	0.08%	65
2022 Q1	$1.15M	Hold	15,885	–	–	0.06%	62
2021 Q4	$1.34M	Hold	15,885	–	–	0.11%	53
2021 Q3	$1.43M	Hold	15,885	–	–	0.15%	61
2021 Q2	$1.51M	Hold	15,885	–	–	0.15%	64
2021 Q1	$1.81M	Sell	15,885 -807	-5%	-$110K	0.19%	54
2020 Q4	$2.31M	Hold	16,692	–	–	0.24%	43
2020 Q3	$1.37M	Hold	16,692	–	–	0.15%	52
2020 Q2	$1.31M	Sell	16,692 -2,876	-15%	-$190K	0.16%	45
2020 Q1	$869K	Sell	19,568 -985	-5%	-$51.1K	0.09%	54
2019 Q4	$878K	Hold	20,553	–	–	0.08%	51
2019 Q3	$879K	Sell	20,553 -2,271	-10%	-$123K	0.07%	58
2019 Q2	$1.45M	Sell	22,824 -2,704	-11%	-$172K	0.09%	58
2019 Q1	$1.77M	Sell	25,528 -3,444	-12%	-$197K	0.11%	57
2018 Q4	$1.26M	Sell	28,972 -25,128	-46%	-$1.37M	0.06%	72
2018 Q3	$4.13M	Hold	54,100	–	–	0.14%	65
2018 Q2	$4.16M	Buy	+54,100	New	+$3.49M	0.12%	65

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

WS Management's RARE Position: Q1 2024 in Review

WS Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2024, closing a stake of 15,885 shares — an estimated $760K sold.

WS Management first reported a position in RARE in Q2 2018 and held it in 23 quarters. The position peaked at $4.16M in Q2 2018. 270 funds tracked by Wall St. Rank hold RARE as of Q1 2024.

WS Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2024 after selling out during the quarter.
WS Management sold 15,885 Ultragenyx Pharmaceutical shares in Q1 2024, an estimated $760K.
WS Management first reported a position in Ultragenyx Pharmaceutical in Q2 2018 and held it in 23 quarters.
WS Management's Ultragenyx Pharmaceutical position peaked at $4.16M in Q2 2018.
270 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2024.

Based on WS Management's 13F filing for Q1 2024, filed 14 May 2024.